Trial Profile
A Randomized, Double Blind, Placebo and Active Controlled, Parallel, Multi-Center Phase IIb Study to Evaluate Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Enclomifene (Primary) ; Testosterone
- Indications Hypogonadism
- Focus Therapeutic Use
- Sponsors Repros Therapeutics
- 16 May 2013 The extension study was completed in January 2013, according to the ClinicalTrials.gov record.
- 16 May 2013 The extension study was completed in January 2013, according to the ClinicalTrials.gov record.
- 28 Dec 2011 It appears that patients enrolled in the extension study prefer to opt for enclomifene versus testosterone treatment, as reported in a Repros Therapeutics media release.